Caring Brands, Inc. (NASDAQ:CABR) Short Interest Update

Caring Brands, Inc. (NASDAQ:CABR) was the recipient of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 20,796 shares, an increase of 278.7% from the May 14th total of 5,492 shares. Currently, 0.3% of the shares of the stock are sold short. Based on an average trading volume of 101,232 shares, the short-interest ratio is presently 0.2 days.

Institutional Investors Weigh In On Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC acquired a new position in Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands at the end of the most recent quarter.

Caring Brands Stock Performance

Shares of NASDAQ:CABR traded up $0.04 during midday trading on Friday, reaching $1.13. The company had a trading volume of 39,341 shares, compared to its average volume of 93,594. The company has a debt-to-equity ratio of 0.03, a quick ratio of 5.62 and a current ratio of 5.66. Caring Brands has a 1-year low of $0.71 and a 1-year high of $5.35. The company has a market capitalization of $10.27 million and a price-to-earnings ratio of -1.77. The company has a fifty day simple moving average of $1.11.

Caring Brands (NASDAQ:CABR) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Caring Brands in a report on Friday, May 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.